The estimated Net Worth of Rosty Raykov is at least $2.3 Million dollars as of 31 August 2024. Rosty Raykov owns over 2,431 units of Fennec Pharmaceuticals Inc stock worth over $349,432 and over the last 7 years Rosty sold FENC stock worth over $1,948,616.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Rosty Raykov FENC stock SEC Form 4 insiders trading
Rosty has made over 14 trades of the Fennec Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Rosty sold 2,431 units of FENC stock worth $13,419 on 31 August 2024.
The largest trade Rosty's ever made was exercising 323,961 units of Fennec Pharmaceuticals Inc stock on 13 August 2020 worth over $599,328. On average, Rosty trades about 27,026 units every 92 days since 2018. As of 31 August 2024 Rosty still owns at least 66,432 units of Fennec Pharmaceuticals Inc stock.
You can see the complete history of Rosty Raykov stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Fennec Pharmaceuticals Inc
Over the last 10 years, insiders at Fennec Pharmaceuticals Inc have traded over $13,607,192 worth of Fennec Pharmaceuticals Inc stock and bought 1,966,488 units worth $9,890,813 . The most active insiders traders include Management Pr, Llcmancheste..., Spacavazza Paolo Cavazza En..., and Rosty Raykov. On average, Fennec Pharmaceuticals Inc executives and independent directors trade stock every 69 days with the average trade being worth of $442,734. The most recent stock trade was executed by Rosty Raykov on 31 August 2024, trading 2,431 units of FENC stock currently worth $13,419.
What does Fennec Pharmaceuticals Inc do?
fennec pharmaceuticals inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the united states. its lead product pedmark, a formulation of sodium thiosulfate, which has completed the phase iii clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. the company was formerly known as adherex technologies inc. and changed its name to fennec pharmaceuticals inc. in september 2014. fennec pharmaceuticals inc. was founded in 1996 and is based in research triangle park, north carolina.
What does Fennec Pharmaceuticals Inc's logo look like?
Complete history of Rosty Raykov stock trades at Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc executives and stock owners
Fennec Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Rostislav Raykov,
Chief Executive Officer, Director -
Shubh Goel,
Chief Commercial Officer -
Robert Andrade,
Chief Financial Officer -
Rostislav Raykov,
CEO & Director -
Shubh Goel,
Chief Commercial Officer -
Robert C. Andrade,
Chief Financial Officer -
Khalid Islam,
Independent Chairman of the Board -
Chris Rallis,
Independent Director -
Adrian Haigh,
Independent Director -
Marco Brughera,
Independent Director -
Jodi Cook,
Independent Director -
Alexander D. Smith M.S.,
Consultant -
Anne McKay,
Regulatory Consultant -
Lei Fang,
Pres of Pharstat Inc -
Mark Gowland,
Controller -
Management Pr, Llcmancheste...,
-
Management Co Llc Mancheste...,
-
Spacavazza Paolo Cavazza En...,
-
Capital Advisors Lp Southpo...,
-
Jeffrey S. Hackman,
Chief Executive Officer -
Rosty Raykov,